Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2001

View Archived Issues

Malaria vaccine MuStDO-5 found safe in preclinical studies

Role of Pgp and the MDR phenotype in gemtuzumab ozogamicin resistance characterized

CV Technologies' combination herbal product shows efficacy in ADHD

Medarex and Genesto to collaborate in developing therapeutic antibodies

Phase II/III study of Onco TCS passes safety review

Aventis and Millennium expand inflammatory disease drug development collaboration

Neuralstem and MetriGenix to develop stem cell-based neurochips for CNS drug discovery

Alliance updates Oxygent development

Dendreon and Kirin broaden cancer vaccine collaboration

Array BioPharma and Icos to discover and develop small-molecule allosteric regulators

Viread NDA set to be reviewed by Antiviral Advisory Committee in October

Genzyme and Theramed establish Canadian marketing collaboration for Thyrogen

Oxford GlycoSciences completes Vevesca NDA submission with FDA

Preliminary phase III results of IM-862 in KS disappointing

Cangene developing new drug technology platform

Intermune completes enrollment in phase III trial of Actimmune for treatment of IPF

Citrus flavonoid inhibits bone resorption

Genaera initiates first clinical trial for Lomucin

Versicor patents novel PDF inhibitors with antibacterial and antimicrobial activity

Serine protease inhibitors identified by researchers at AxyS

Sanofi-Synthelabo reports compounds useful for treating urinary incontinence

A new series of MMP inhibitors described by Darwin Discovery

Sumitomo designs new NHE inhibitors

Prevention of bone destruction by leflunomide

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...